Finanzas de Alpha Teknova Inc (TKNO)TKNOAlpha Teknova Inc

Alpha Teknova, Inc. (TKNO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Lab Essentials, accounting for 75.8% of total sales, equivalent to $8.39M. Other significant revenue streams include Clinical Solutions and Other. Understanding this composition is critical for investors evaluating how TKNO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Alpha Teknova, Inc. maintains a gross margin of 37.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23.72%, while the net margin is -26.02%. These profitability ratios, combined with a Return on Equity (ROE) of -24.19%, provide a clear picture of how effectively TKNO converts its operational activities into shareholder value.

In the context of the broader market, TKNO competes directly with industry leaders such as EYPT and ENTA. With a market capitalization of $391.39M, it holds a significant position in the sector. When comparing efficiency, TKNO's gross margin of 37.73% stands against EYPT's 100.00% and ENTA's 100.00%. Such benchmarking helps identify whether Alpha Teknova, Inc. is trading at a premium or discount relative to its financial performance.

Alpha Teknova has shown significant revenue growth, with Q2 2026 revenue at $12.185 million, marking the highest quarterly revenue in its history. The gross margin has improved to 37.73%, indicating better profitability.